These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 5828530)

  • 21. Substantia nigra tangles are related to gait impairment in older persons.
    Schneider JA; Li JL; Li Y; Wilson RS; Kordower JH; Bennett DA
    Ann Neurol; 2006 Jan; 59(1):166-73. PubMed ID: 16374822
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Essential tremor associated with focal nonnigral Lewy bodies: a clinicopathologic study.
    Louis ED; Honig LS; Vonsattel JP; Maraganore DM; Borden S; Moskowitz CB
    Arch Neurol; 2005 Jun; 62(6):1004-7. PubMed ID: 15956174
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Modeling parkinsonism (review)].
    Atadzhanov M
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1982; 82(3):110-9. PubMed ID: 6805182
    [No Abstract]   [Full Text] [Related]  

  • 24. Evaluation of tremor disorders.
    Koller WC
    Hosp Pract (Off Ed); 1990 May; 25(5A):23, 26-7, 30-1. PubMed ID: 2111823
    [No Abstract]   [Full Text] [Related]  

  • 25. Iron in the Parkinsonian substantia nigra.
    Gerlach M; Double K; Riederer P; Hirsch E; Jellinger K; Jenner P; Trautwein A; Youdim MB
    Mov Disord; 1997 Mar; 12(2):258-60. PubMed ID: 9087993
    [No Abstract]   [Full Text] [Related]  

  • 26. Pathogenesis of nigral cell death in Parkinson's disease.
    Przedborski S
    Parkinsonism Relat Disord; 2005 Jun; 11 Suppl 1():S3-7. PubMed ID: 15885625
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [A 62-year-old man with familial parkinsonism with the onset at 24 years of the age].
    Takubo H; Kondo T; Mori H; Miyake T; Suda K; Yokochi M; Imai H; Mizuno Y
    No To Shinkei; 1996 Jun; 48(6):587-97. PubMed ID: 8703564
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [An autopsied case of progressive spinal muscular atrophy showing tremor and choreiform movement].
    Kaneto T; Inoue K; Shimoda K; Doi M; Kitagawa T; Kumada H; Miyata H; Ohama E
    Rinsho Shinkeigaku; 2000 Aug; 40(8):801-6. PubMed ID: 11218700
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Juvenile parkinsonism: its neuropathological aspects].
    Takahashi H
    No To Shinkei; 1994 Jun; 46(6):523-9. PubMed ID: 8068433
    [No Abstract]   [Full Text] [Related]  

  • 30. Hemiparkinsonism and levodopa-induced dyskinesias following focal nigral lesion.
    Alves R; Barbosa E; Scaff M
    Mov Disord; 2006 Dec; 21(12):2267-8; author reply 2268. PubMed ID: 17078068
    [No Abstract]   [Full Text] [Related]  

  • 31. Topographical alterations of the midbrain and the substantia nigra following unilateral posteroventral pallidotomy in patients with Parkinson's disease using routine and multishot diffusion-weighted magnetic resonance imaging.
    Adachi M; Kurimura M; Saito S; Hosoya T; Kayama T; Kato T
    Neuroradiology; 2002 Jul; 44(7):579-85. PubMed ID: 12136359
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neuromelanin magnetic resonance imaging of locus ceruleus and substantia nigra in Parkinson's disease.
    Sasaki M; Shibata E; Tohyama K; Takahashi J; Otsuka K; Tsuchiya K; Takahashi S; Ehara S; Terayama Y; Sakai A
    Neuroreport; 2006 Jul; 17(11):1215-8. PubMed ID: 16837857
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The protective role of levodopa in the human substantia nigra.
    Rajput AH
    Adv Neurol; 2001; 86():327-36. PubMed ID: 11553992
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Iron and ferritin in substantia nigra in Parkinson's disease.
    Jellinger KA; Kienzl E; Rumpelmaier G; Paulus W; Riederer P; Stachelberger H; Youdim MB; Ben-Shachar D
    Adv Neurol; 1993; 60():267-72. PubMed ID: 8420142
    [No Abstract]   [Full Text] [Related]  

  • 35. [An autopsy case of striato-nigral and olivo-ponto-cerebellar degeneration (author's transl)].
    Riku S; Hashizume Y; Yanagi T; Sobue I
    Rinsho Shinkeigaku; 1980 Jul; 20(7):534-8. PubMed ID: 7460423
    [No Abstract]   [Full Text] [Related]  

  • 36. The substantia nigra in Parkinsonism.
    Wolman L; Roy S
    J Clin Pathol; 1969 Jul; 22(4):507-8. PubMed ID: 5798646
    [No Abstract]   [Full Text] [Related]  

  • 37. Possible role of cerebellar circuits in parkinsonian symptoms.
    Narabayashi H
    Confin Neurol; 1974; 36(4-6):292-301. PubMed ID: 4218802
    [No Abstract]   [Full Text] [Related]  

  • 38. Juvenile parkinsonism--some clinical, pharmacological, and neuropathological aspects.
    Yokochi M; Narabayashi H; Iizuka R; Nagatsu T
    Adv Neurol; 1984; 40():407-13. PubMed ID: 6141711
    [No Abstract]   [Full Text] [Related]  

  • 39. Early signs of neuronal apoptosis in the substantia nigra pars compacta of the progressive neurodegenerative mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid model of Parkinson's disease.
    Novikova L; Garris BL; Garris DR; Lau YS
    Neuroscience; 2006 Jun; 140(1):67-76. PubMed ID: 16533572
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [L-dopa-resistant parkinsonism with cerebral atrophy: striato-nigral degeneration? 2 cases].
    Dell'Aria V; Ciannella L; Melone MA
    Acta Neurol (Napoli); 1981 Feb; 3(1):212-5. PubMed ID: 7246294
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.